During direct compression of yolk antibody powder into fast-disintegrating canine oral tablets, the controlling variable is the water activity of the API–excipient blend rather than the compression force alone. The veterinary-grade IgY powder is conditioned at 25°C ± 2°C and ≤40% relative humidity until moisture drops below 5.0% w/w; above 6.0% w/w moisture, punch sticking and capping are observed on rotary presses because hydrated protein films form on the punch face during dwell times exceeding 50 ms. The API is incorporated at 15–25% w/w of the dry core, delivering 80–150 mg yolk antibody per unit dose. Raw API lots are pre-blended to an ELISA titre of ≥1:256 against target parvovirus and coronavirus antigens, then mixed in a bin blender at 12–15 rpm for 15 min. Dry granulation is performed on a roller compactor at 4–6 kN/cm² roll force and 0.8 mm screen milling to avoid the aqueous wet-granulation step that would expose IgY to 40–50°C drying. The final core blend contains crospovidone 2–4% w/w, microcrystalline cellulose 30–40% w/w, and magnesium stearate 0.5–1.0% w/w. Tablets are compressed on a rotary press at 8–12 kN to hardness 50–70 N, friability ≤1.0%, and disintegration ≤15 min in 0.1 mol/L phosphate buffer at pH 6.8. Capsules use the same granulation filled into size 3 or 4 gelatine capsules under ≤40% RH. Compliance is assessed under USP <905>, USP <701>, and in-process sampling under 21 CFR 211.110. Terminal forms are oral tablets and immediate-release capsules.

How Does Fluidised-Bed Agglomeration Preserve IgY Activity in Calf Milk Replacer Granules?

Fluidised-bed agglomeration rather than high-shear wet granulation is selected because the residence time of wetted mass at product temperature above 40°C can reduce specific antibody binding activity by more than 20% within 30 min, a loss detectable by ELISA and by haemagglutination inhibition titre. The granulation line operates with inlet air at 45–55°C and product bed temperature 35–40°C, spraying a 5–10% w/w maltodextrin binder solution at 0.8–1.2 L/min per 100 kg batch. Yolk antibody API is pre-blended into the dry milk replacer base at 0.10–0.30% w/w, equivalent to 100–300 mg IgY per calf per day at 200 g/day dry matter intake. The resulting agglomerates are sieved to 100–1200 µm; fines below 100 µm are recycled into the spray zone to reduce segregation in packaging. The product is cooled to ≤25°C and packed in aluminium-lined bags with desiccant to keep headspace relative humidity below 30%. Disease targets are neonatal calf diarrhoea pathogens including E. coli K99 (F5), rotavirus, and bovine coronavirus; the API lot release specification includes an ELISA titre of ≥1:256 against each relevant antigen. Terminal forms are water-dispersible granules and reconstitutable powders. Compliance is managed under ISO 22000:2018 and CAC/RCP 54-2004; where classified as a feed additive or dietetic feed in the EU, the product requires a dossier under Regulation (EC) No 1831/2003.

At 0.05–0.15 g/L, yolk antibody water-soluble powder remains active only if the reconstituted solution resists free chlorine and pH drift in poultry drinking water lines. The premix is blended with citrate–phosphate buffer to maintain pH 6.0–6.5 after dilution and with lactose or glucose monohydrate at 30–50% w/w as a dispersant. Reconstitution is performed at 15–25°C in potable water with free chlorine ≤0.1 mg/L; if source chlorine exceeds 0.1 mg/L, sodium thiosulfate is pre-dissolved at 0.5–1.0 g/L and the chlorine residual is re-tested before IgY addition. The medicated solution is delivered through a proportioner pump set between 1:50 and 1:200, with a stock solution at 100 g/L corresponding to 0.05–0.15% w/w IgY. Agitation is performed with a low-shear impeller at 50–100 rpm for 10–15 min; no post-dissolution heating is used because IgY antigen-binding fragments denature above 60°C in aqueous solution. The medicated water is consumed within 24 h, and the delivery system is flushed with plain water to prevent biofilm accumulation. The terminal dosage types are soluble powders and oral solutions. Compliance references ISO 22000:2018 and CAC/RCP 54-2004; water medicator accuracy is verified by gravimetric calibration against the manufacturer’s stated dilution curve at 1:50 and 1:200. Target pathogens are Salmonella Enteritidis, Salmonella Typhimurium, and avian pathogenic E. coli O78.

When Post-Weaning Scour Control Requires Heat-Labile IgY, Pellet Top-Dressing Replaces Pre-Mix Extrusion

Post-weaning E. coli F4 and F18 challenge in piglets is managed by applying yolk antibody API after pelleting because conventional compound feed conditioning at 75–85°C exceeds the safe processing limit of IgY and would reduce ELISA titre below the release specification. The API is first diluted into a 1.0% premix at 100–300 g/kg using lactose or maltodextrin carrier dried to ≤4.0% moisture, then applied to cooled pellets at 1.0–3.0 kg/tonne of finished feed, equivalent to 0.1–0.3% w/w. A horizontal ribbon mixer with paddle tip speed 1.5–2.5 m/s is run for 8–12 min to achieve a coefficient of variation below 5.0%; segregation is measured by sampling at 10 points according to ISO 6497:2002. If carrier bulk density differs from the pellet bulk density by more than 0.1 g/mL, the mixing time is extended to 15 min and the batch is re-tested. The finished premix is packed in 25 kg PE-lined paper bags and stored at ≤25°C and ≤40% RH. Terminal forms are granular premixes and top-dress powders. Compliance is managed under ISO 22000:2018; in the EU, feed additive claims fall under Regulation (EC) No 1831/2003. If a pelleted product is unavoidable, post-pelleting vacuum coating is used with pellet temperature below 45°C and a fat-based suspension delivery at 0.5–1.0% w/w fat.

Vacuum Coating of Post-Extruded Shrimp Pellets with Anti-Vibrio IgY

In marine shrimp hatcheries and grow-out ponds, oral passive immunization against Vibrio parahaemolyticus and Vibrio harveyi requires the IgY API to survive the lipid-coating step after extrusion. Shrimp feed pellets are produced on a twin-screw extruder with a length-to-diameter ratio of 25:1, barrel temperature profile 90–105–110°C, and die diameter 1.2–2.0 mm; the extruded pellets are dried to ≤10% moisture and cooled to ≤45°C before coating. A vacuum coater then sprays a fish-oil suspension of yolk antibody powder at 0.5–2.0 g/kg finished feed, with total oil uptake controlled at 2–4% w/w and lecithin emulsifier at 0.1–0.5% w/w. The coater operates at 0.5–0.8 bar absolute pressure for 10–15 min, drawing the oil suspension into the porous pellet surface without wet heat. Oil temperature is held at 25–35°C; excursions above 40°C are corrected by reducing jacket temperature. The coated pellets are cooled, packed under nitrogen, and stored at ≤25°C. Terminal forms are coated granules and sinking pellets. Process verification includes ELISA titre retention after coating; a titre loss above 20% triggers corrective adjustment of oil temperature and contact time. Compliance uses ISO 22000:2018 and the Codex code of practice CAC/RCP 52-2003 as the food-safety reference adapted to aquaculture feed. Addition ratios for fish diets targeting Edwardsiella ictaluri appear as 1.0–5.0 g/kg in experimental literature; commercial shrimp feed data for this specific configuration is limited, so batch-specific challenge titration is used to set the final inclusion.

Aseptic Ultrafiltration and Sterile Filtration Parameters for Investigational IgY Injectables

Injectable yolk antibody solutions are prepared only where parenteral passive immunization is justified, and the downstream process is restricted by the need to remove lipoproteins and pyrogenic chick-egg proteins. The API is dissolved in water for injection at 10–20 mg/mL total protein; the pH is adjusted to 7.4 with 0.01 mol/L phosphate-buffered saline. Continuous centrifugation at 10,000 × g for 15 min removes coarse lipoproteins, followed by tangential-flow ultrafiltration across a 10 kDa polyethersulfone membrane for 5–7 diafiltration volumes. The intermediate solution is filtered through 0.45 µm and then 0.22 µm sterilising-grade membranes, and filled into Type I glass vials under Grade A (ISO 5) conditions in an ISO 14644-1:2015 cleanroom. Endotoxin is controlled below 0.5 EU/mL; subvisible particles are monitored under USP <787>; sterility is tested under USP <71>; aseptic processing controls follow 21 CFR 211.113. Terminal dosage form is a parenteral solution, with lyophilised powder as an alternative when a freeze-dry cycle is run from shelf temperature -20°C to +20°C over 24–36 h and residual moisture ≤3.0%. Repeated parenteral administration in non-avian species is limited by the immunogenicity of chicken immunoglobulin, and published data for specific veterinary injection indications is limited; this dosage form is therefore confined to single-dose toxin-neutralisation protocols or investigator-led efficacy studies.